Evaluation of the Water Vapor Thermal Therapy System for the Treatment of Benign Prostatic Hyperplasia

Inclusion Criteria: * Men aged 45-80 years (inclusive) with symptoms secondary to BPH and requiring invasive intervention. * International Prostate Symptom Score (IPSS) ≥13 points. * Maximum urinary flow rate (Qmax): ≤15 ml/s, with a minimum urine volume of ≥125 ml. * Post-urination residual urine volume (PVR): ≤250 ml. * Prostate volume measured by MRI: 30\~80 cm³ (including 30 cm³ and 80 cm³). * Voluntarily participate in the clinical trial and sign the informed consent form. Exclusion Criteria: * Malignant lesions of the urinary system, such as prostate cancer or bladder cancer, or other systemic advanced malignant tumors (e.g., gastric cancer, liver cancer, lung cancer). * Patients with difficulty inserting instruments due to urethral stenosis or bladder neck contracture. * Severe coagulation disorder. * Urinary incontinence caused by reduced sphincter function or severe urge urinary incontinence. * Patients with a history of severe cardiovascular disease, including but not limited to: * Second/third-degree heart block. * Severe ischemic heart disease. * Congestive heart failure with New York Heart Association (NYHA) heart function grade ≥ II (mild physical activity limitation; comfortable at rest, but normal activities can cause fatigue, palpitations, or dyspnea). * Prostate biopsy within 2 months before enrollment. * Unstable angina, myocardial infarction, transient ischemic attack, or cerebrovascular accident in the past 6 months. * Patients with previous invasive prostate treatment, such as: * Radiofrequency (RF) ablation. * Balloon dilation. * Microwave therapy. * Laser treatment. * Electroreception. * Prostate urethral stent. * Suspension procedures. * History of previous rectal surgery (except hemorrhoidectomy) or history of rectal disease that affects the treatment method or efficacy evaluation in this study. * Acute urinary and reproductive system infections that are not effectively controlled. * Neurogenic bladder or neurological diseases that affect bladder function, sphincter function, or detrusor function, as assessed by the researcher. * Bladder stones. * Subjects who cannot undergo MRI examination. * Subjects who are: * Currently participating in clinical trials. * Have participated in other drug clinical trials within 3 months. * Have participated in other medical device clinical trials within 30 days. * Other situations that the researcher believes are unsuitable for participation in the study.